{"id":10620,"date":"2019-10-29T18:49:05","date_gmt":"2019-10-29T17:49:05","guid":{"rendered":"https:\/\/udic.es\/?p=10620"},"modified":"2019-11-07T18:50:52","modified_gmt":"2019-11-07T17:50:52","slug":"dental-germ-in-patients-with-moderate-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/dental-germ-in-patients-with-moderate-alzheimers-disease\/","title":{"rendered":"Dental germ in patients with moderate Alzheimer’s disease"},"content":{"rendered":"
We are developping a clinical trial that evaluates the efficacy and safety of an oral medication that inhibits an enzyme released by a dental germ<\/a> in patients with moderate Alzheimer’s disease. <\/span><\/p>\n The GAIN trial (code COR388-010) is a phase III clinical trial and we are carrying out in Spain, in the General University Hospital of Catalonia<\/a>, with the collaboration between the services of neurology, neuropsychology, neuroradiology and odontology, coordinated by Dr. Balaguer, neurologist and director of research.<\/span><\/p>\n<\/a><\/p>\n